|
|
|
| Analysis on medical device recall from 2010 to 2018 in China |
| ZHANG Huan1 HONG Yuan2 HE Yuqing2 ZHANG Lei3 CHEN Qi4 YAO Wen5 LIU Liping2 |
1.Department of Parmacy, Kangda College of Nanjing Medical University, Jiangsu Province, Lianyungang 222000, China;
2.Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Jiangsu Province, Nanjing 211166, China;
3.Jiangsu Hengrui Pharmaceutical Co., Ltd, Jiangsu Province, Wuxi 214000, China;
4.Department of Finance, Sanjiang University, Jiangsu Province, Nanjing 210012, China;
5.Department of Humanities and Management, Kangda College of Nanjing Medical University, Jiangsu Province, Lianyungang 222000, China |
|
|
|
Abstract Objective To explore the status quo of medical device recall in China and to make recommendations for reference. Methods All information were collected in “Medical Device Recall” section of the official websites of China Food and Drug Administration (CFDA) and National Medical Products Administration (NMPA) from May 2010 to December 2018. Excel method was used for classification analysis in terms of number of recalls, reasons, levels, methods, equipment classification, country of origin, and manufacturing enterprises. Results The total number of effective medical device recalls was 1533 cases, all of which were active recalls, including 1251 cases of imported instruments (81.60%) and 282 cases of domestic instruments (18.40%). The main recall reasons were design defects in 349 cases (22.77%) and manufacturing defects in 752 cases (49.05%). 48 cases (3.13%) were recalled with first level, 379 cases (24.72%) with second level, while 740 cases (48.27%) with third level, and 366 cases (23.87%) with un-indicated recall level. The number of Clinical analytical instruments recalls was 403 cases (26.29%), which was the largest number in category of devices recalls. 18 countries were involved in the recall process, while the top 3 were USA, China and Germany. Conclusion The recall regulation has achieved remarkable results, however, the system still needs to be standardized to improve the scientific and efficient supervision system.
|
|
|
|
|
|
[1] 国家食品药品监督管理总局.医疗器械召回管理办法[S].国家食品药品监督管理总局令第29号，2017-5-1.
[2] 王伟明，李路明，郝红伟，等，对2006～2015年美国FDA召回的神经调控类医疗器械产品分析[J].中国医疗器械信息，2015，5（21）：20-25.
[3] 王宝亭，耿鸿武，于清明，等.中国医疗器械行业发展报告（2018）[M].北京：社会科学文献出版社，2018.
[4] 张强，刘胜林，严毅，等.对2005～2006年美国FDA召回的医疗器械产品分析[J].中国医疗器械杂志，2011，35（4）：280-283.
[5] 焦艳玲，焦彦洪.论美国药品缺陷责任对我国的启示[J].中国药房，2013，24（37）：3457-3459.
[6] CFDA.医疗器械分类目录[EB/OL].（2002-08-28）[2017-06-18].http：//www.sda.gov.cn/gyx02302/flml.htm.
[7] 张倩，冯靖祎，吕颖莹，等.2018年上半年医疗器械召回情况探讨[J].中国医疗设备，2018，33（12）：151-153，156.
[8] CFDA.数据查询[EB/OL].[2017-04-21].http：//app1.sfda.gov.cn/datasearch/face3/dir.html.
[9] 李锐峰.中国医疗器械市场分析[J].中国外资月刊，2011（252）：123-125.
[10] 王哲，王爱平，崔瞳，等.国产医疗器械配置模式研究进展[J].中国医学装备，2019，16（2）：133-136.
[11] 兰秀梅.医疗器械不良事件监管分析[J].山东工业技术，2017（6）：289-289.
[12] 卞蓉蓉，郑建立，徐厚明，等.16706例可疑医疗器械不良事件报告分析[J].中国医疗器械信息，2014，3（20）：37-41.
[13] 郭柯磊，欧阳昭连，杜然然，等.中国医疗器械不良事件报告现状[J].北京生物医学工程，2012，31（5）：518-523.
[14] 施雯慧，姚捷，赵燕.美国医疗器械不良事件报告数据库研究[J].中国医药导报，2014，11（28）：148-152.
[15] Ross JS. Strengthening medical device postmarket safety surveillance [J]. JAMA Int Med，2015，175（8）：1350-1351.
[16] 朱书敏，徐晓媛.美国医疗器械上市后监测体系运行经验及启示[J].中国医疗器械杂志，2017，41（2）：123-126.
[17] 戴世斌，崔蕾，孙忠根，等.风险管理在医院医疗器械管理中的应用效果及对管理质量的影响研究[J].中国医学装备，2019，16（1）：125-128.
[18] Jim B. What is product recall insurance [EB/OL].（2014-03-01）[2015-10-29]. http：//www.wisegeek.com/what-isproduct-recall-insurance.html.
[19] 蔡娟娟，吴秋一，陈其，等.基于官方网站信息分析我国药品召回现状及存在的问题[J].中国药房，2016，27（13）：1742-1745.
[20] Caines P. Global post market surveillance-effectively manage complaints and meet regulatory challenges in international markets [EB/OL]. 2014-06-19.http：//www.cbinet.com/sites/default/files/files/session%2010pres_cain-es_updated.pdf.
[21] 蒋海洪，杨悦.我国医疗器械管理制度发展评析与展望[J].沈阳药科大学学报，2018，35（5）：89-93，106.
[22] 胡少科，朱未，刘胜林，等.基于德尔菲法与层次分析法对在用医疗器械质量管理评价指标体系的构建与应用研究[J].中国医学装备，2018，15（5）：105-109.
[23] 吴维民，韦波，庞家玲，等.广西医疗机构医疗器械使用质量评价指标体系的构建研究[J].现代医院，2019，19（4）：522-524，528. |
|
|
|
